VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the Cerebrospinal fluid of preterm infants can be used as a biomarker to predict the risk for developing white matter damage.
Condition or disease
Preterm Infants With White Matter DamagePreterm Infants Developing Normally
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
25 Weeks to 40 Weeks (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Preterm infants undergoing lumbar puncture.
Preterm with IVH or known infection or meningitis.